InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $2.160

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,811 Change in substantial holding 16 Dec 2024 8:30AM $1.840 $2.160 risen by 17.39%
$2,811 Material Announcement 5 Dec 2024 11:01AM $1.760 $2.160 risen by 22.73%
$2,811 Pause in Trade 5 Dec 2024 10:00AM $1.760 $2.160 risen by 22.73%
$2,811 FDA Grants Mesoblast RMAT Designation 5 Dec 2024 9:59AM $1.760 $2.160 risen by 22.73%
$2,811 REVASCOR Improves Survival & Reduces Major Morbidity 3 Dec 2024 9:46AM $1.800 $2.160 risen by 20%
$2,811 Becoming a substantial holder 21 Nov 2024 8:18AM $1.575 $2.160 risen by 37.14%
$2,811 Results of Meeting 15 Nov 2024 5:17PM $1.570 $2.160 risen by 37.58%
$2,811 Final Director's Interest Notice 15 Nov 2024 5:11PM $1.570 $2.160 risen by 37.58%
$2,811 CEO Presentation to 2024 Annual General Meeting 15 Nov 2024 11:51AM $1.605 $2.160 risen by 34.58%
$2,811 Mesoblast Chair Message to 2024 AGM 15 Nov 2024 11:47AM $1.590 $2.160 risen by 35.85%
$2,811 Response to ASX Price Query 14 Nov 2024 3:42PM $1.790 $2.160 risen by 20.67%
$2,811 Notification regarding unquoted securities - MSB 12 Nov 2024 8:07PM $1.515 $2.160 risen by 42.57%
$2,811 Warrant Prospectus Related to Convertible Note Agreement 7 Nov 2024 7:15PM $1.350 $2.160 risen by 60%
$2,811 Ceasing to be a substantial holder 5 Nov 2024 8:16AM $1.280 $2.160 risen by 68.75%
$2,811 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2024 9:44AM $1.345 $2.160 risen by 60.59%
$2,811 Annual Report to Shareholders 17 Oct 2024 1:29PM $1.445 $2.160 risen by 49.48%
$2,811 Notice of Annual General Meeting and Proxy Form 17 Oct 2024 1:17PM $1.450 $2.160 risen by 48.97%
$2,811 Appendix 4G and Corporate Governance Statement 17 Oct 2024 1:07PM $1.435 $2.160 risen by 50.52%
$2,811 Notification of cessation of securities - MSB 11 Oct 2024 5:44PM $1.450 $2.160 risen by 48.97%
$2,811 Notification regarding unquoted securities - MSB 11 Oct 2024 5:44PM $1.450 $2.160 risen by 48.97%
$2,811 Change in substantial holding 10 Oct 2024 1:34PM $1.385 $2.160 risen by 55.96%
$2,811 Becoming a substantial holder 9 Oct 2024 8:25AM $1.465 $2.160 risen by 47.44%
$2,811 Proposed issue of securities - MSB 30 Sep 2024 10:10AM $1.155 $2.160 risen by 87.01%
$2,811 Mesoblast Option to Issue up to US$50m Convertible Notes 30 Sep 2024 9:59AM $1.125 $2.160 risen by 92%
$2,811 Ceasing to be a substantial holder 27 Sep 2024 8:18AM $1.090 $2.160 risen by 98.17%

251 - 275 of 1203 results

Page 11 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.